Frontlight ResearchEarly access
Taking peoplePhase 2
Stool-based capsules for immune activation in people with cirrhosis and fluid buildup
Tests the safety of fecal microbiota capsules in adults with cirrhosis and ascites.
Key facts
- Who runs it
- Universitaetsklinikum Aachen AöR
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, double-blind, placebo-controlled phase IIa clinical pilot study
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 24 people, planned
- Started
- 1 Aug 2025
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional
- Record updated
- 22 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis (scarring of the liver) and fluid in the belly (ascites). It tests the safety of capsules with stool bacteria from donors (FMT) against placebo.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Cirrhosis of any cause, with ascites. Fluid must have been drained or sampled from the belly within the last 30 days. MELD score must not be above 20. Acute-on-chronic liver failure grade 2 or higher is not allowed.
- Earlier treatment
- No systemic antibiotics in the 7 days before joining, except stable doses of norfloxacin or rifaximin. No immune-modifying drugs now or in the 90 days before joining. No investigational drug in another study in the last 30 days.
Main reasons for not taking part
- Active cancer, or past cancer not fully treated (except non-melanoma skin cancer)
- Active bacterial infection at the start
- Known immune deficiency, such as HIV infection
- Pregnant or breastfeeding
- Expected to live less than six months
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Subject has cirrhosis of any etiology based on clinical standard criteria, imaging findings, and/or histology
- Subject is diagnosed with ascites and has undergone paracentesis or diagnostic ascitic tap within the last 30 days prior to study inclusion
- Subject age is between 18 and 70 years at the time of study inclusion
- Subject is able to swallow the Investigational Medicinal Product (IMP) Fecal Microbiota Transfer capsules or placebo
- Subject is mentally and physically able to understand the significance and scope of the study and to comply with the study protocol
- A written informed consent form has been signed prior to participation in the study
Who cannot take part
- Subject has received systemic antibiotics within 7 days prior to study inclusion, except for stable doses of norfloxacin or rifaximin
- Subject receives treatment with immunomodulatory drugs (prednisolone, prednisone, methylprednisolone, hydrocortisone, dexamethasone, azathioprine, mercaptopurine, tacrolimus, mycophenolate, cyclosporine, sirolimus, everolimus, hydroxychloroquine, leflunomide, methotrexate, infliximab, adalimumab, etanercept, rituximab, anakinra, tofacitinib, upadacitinib, natalizumab, basiliximab), currently or within 90 days prior to study inclusion
- Study participation is, at the discretion of the investigator, an unacceptable risk due to pre-existing or concomitant disease or due to the patient's general underlying condition
- Subject has received an investigational drug in another study within the last 30 days before study inclusion
- Concurrent participation in another clinical intervention study
- Subject has acute-on-chronic liver failure (ACLF) grade 2 or higher according to the EASL-CLIF Consortium definition
- Subject has active malignancy or history of malignancy, which was not curatively treated (excluding non-melanoma skin cancer)
- Subject has a history of hypersensitivity or allergies to the investigational capsule coating substances or to any compound of INTESTIFIX 001 or placebo
- Subject has active bacterial infection at inclusion
- Subject has known primary immunodeficiency (e.g., Bruton disease or common variable immunodeficiency) or secondary immunodeficiency (e.g., HIV infection)
- There is a current or past medically relevant disease or treatment that could influence the evaluation of the study
- Subject has Model for End-Stage Liver Disease (MELD) score >20
- Subject has an expected lack of compliance
- Subject has a life expectancy of less than six months
- Subject is pregnant or breastfeeding
- Subject is not willing to take adequately safe contraceptive measures
- Subject is institutionalized due to an official or court order
- Subject is in a dependent relationship or employment relationship with the sponsor or investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety of FMT capsules for the treatment of immune activation in patients with cirrhosis and ascites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, double-blind, placebo-controlled phase IIa clinical pilot study
- Plain-language title
- Stool-based capsules for immune activation in people with cirrhosis and fluid buildupGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 22 July 2026